Sector News

Illumina acquires Conexio Genomics

January 27, 2016
Life sciences

(GenomeWeb) – Illumina announced today that it has acquired Australian HLA typing solutions provider Conexio Genomics.

Terms of the deal were not disclosed.

Illumina first partnered with Conexio in March 2015 to offer the TruSight HLA Solution, a sequencing-based product for accurate HLA typing across thousands of known and novel HLA alleles. The product uses Conexio’s Assign software for analysis and reporting.

The acquisition will enable Illumina to develop NGS-based transplant diagnostics assays, including a new solution for interrogating genomic variants in the gamma genomic block of the major histocompatibility complex, the company said in a statement.

“The addition of Conexio products and people solidify our HLA capabilities and demonstrate Illumina’s ongoing commitment to HLA and ultimately to the field of transplant science,” Alex Lindell, Illumina’s associate director of market development for HLA, said in the statement.

Conexio’s NGS development programs will be folded into Illumina’s existing business units.

comments closed

Related News

February 25, 2024

Pharma CFOs need R&D vigilance in tough economic times

Life sciences

As inflation, high interest rates and a tight investment environment continue to create headaches, 72% of CFOs said economic volatility poses the same or greater risk to their business this year compared to 2023 in a recent survey from BDO — and there are more changes afoot.

February 25, 2024

Agilent CEO Mike McMullen to retire, succeeded by lab services head

Life sciences

McMullen, who’s also currently president of Agilent, is set to abdicate both roles on May 1, according to an announcement the company put out Wednesday afternoon. From there, McMullen will spend a few months serving as an advisor to Agilent and to his successor until his retirement becomes final on Oct. 31.

February 25, 2024

AstraZeneca completes Gracell Biotechnologies acquisition for $1.2bn

Life sciences

AstraZeneca has concluded its acquisition of China-based clinical-stage biopharmaceutical company Gracell Biotechnologies for $1.2bn. The acquisition, initially agreed in December 2023, positions Gracell as a wholly owned AstraZeneca subsidiary with operations continuing in the US and China.

How can we help you?

We're easy to reach